Rama Boppana
Acute Care · Durham, NCNPI 1033869631
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 62.5% of it on its own, with 16 other manufacturers making up the rest.
Across 43 payments — averaging $41.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$1K
- Lilly USA, LLC$121
- Merck$80
- Averitas Pharma Inc.$69
- AstraZeneca$56
- Novo Nordisk$55
- plus $295 from 11 others
What the payments were for
- Travel & lodging$92752%
- Food & beverage$85347%
- Education$201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 10 | $1,124 |
| Lilly USA, LLC | 6 | $121 |
| Merck | 4 | $80 |
| Averitas Pharma Inc. | 2 | $69 |
| AstraZeneca | 3 | $56 |
| Novo Nordisk | 3 | $55 |
| Bayer | 3 | $54 |
| Aucta Pharmaceuticals, Inc. | 3 | $39 |
| Banner Life Sciences, LLC | 1 | $31 |
| Baxter Healthcare | 1 | $26 |
| Recordati_rare_diseases_inc. | 1 | $25 |
| Neurelis, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| AbbVie | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$862
How this compares
$1,799 in reported general payments places this provider in the 85th percentile of 312 acute care providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 483 | $634,230 |
| JardianceEmpagliflozin | 308 | $314,276 |
| FarxigaDapagliflozin Propanediol | 165 | $138,900 |
| KerendiaFinerenone | 125 | $112,766 |
| RybelsusSemaglutide | 73 | $107,163 |
| MounjaroTirzepatide | 80 | $87,567 |
| Tresiba Flextouch U-100Insulin Degludec | 158 | $86,764 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $70,327 |
| TrulicityDulaglutide | 55 | $67,235 |
| Humalog Kwikpen U-100Insulin Lispro | 84 | $27,030 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 13 | $24,328 |
| Novolog FlexpenInsulin Aspart | 68 | $14,857 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 107 | $13,007 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $11,518 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 43 | $8,953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $55 | $745,131572 claims |
| Lilly USA, LLCMounjaro, Trulicity | $121 | $154,801135 claims |
| AstraZenecaFarxiga | $56 | $138,900165 claims |
| BayerKerendia | $54 | $112,766125 claims |
| AbbVieSynthroid | $16 | $2,25142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 312 acute care providers in North Carolina.
Other acute care in Durham
- Adrienne BranchDurham$4K
- Elynelle Joy MoajeDurham$3K
- Zachary LennonDurham$2K
- Lisa McDonaldDurham$2K
- Benjamin HocuttGreenville$25K
- Matthew KuhnPinehurst$16K
- Robin TruppApex$14K
- Suzanne HartmannRaleigh$12K
- Leigh CasperSalisbury$12K
- Juliana QuagraineCharlotte$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.